Souhaitez-vous accéder aux communiqués récents ?

Kraig Labs (OTCQB: KBLB) CEO featured in an extensive interview with Pulse 2.0, where he discussed the Company's technological leadership, commercial produ

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient...

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case...

Kraig Labs (OTCQB: KBLB) completed its largest production cycle in the Company's history, producing nearly 2.5 metric tons of spider silk cocoons

Austin, TX, USA, June 03, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “CRISPR-based Gene Editing Market Size, Trends and Insights By Product (Kits and...

Kraig Labs (OTCQB: KBLB) spider silk cocoon collection, for its current production cycle, show early production yields exceeding targets by 20%.

Austin, TX, USA, May 21, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Genome Editing Market Size, Trends and Insights By Technology (CRISPR)/Cas9,...

Kraig Labs (OTCQB: KBLB) provides additional details regarding the significant advantages of its newly developed immortalized silk gland cell platform

Kraig Labs (OTCQB:KBLB) latest breakthrough could form the foundation for a next-generation biotechnology platform with potential applications in biopharma

Austin, TX, USA, May 14, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Transgenic Animals Market Size, Trends and Insights By Type (Mice, Rats, Rabbits,...